ArticleScientific reports2025
Doxorubicin loaded polylactide nanoparticles functionalized histamine promote apoptosis of human gastric cancer cells AGS.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- pH-responsive acetylated PAMAM dendrimer nanocarriers for enhanced intravesical delivery of Erdafitinib in urothelial carcinoma.Scientific reports · 2026Article
- Development of 3D spheroids of AGS gastric cancer cellsFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a dominating cause of cancer-related deaths in the world. The modern perspective in gastric cancer treatment is the application of nanoparticles (NPs) affecting the growth of cancer cells to increase the effectiveness of anti-tumor therapy. The use of advanced nanosystems that deliver anti-cancer drugs and biologically active substances may strongly rely on the expression of cancer-associated targets. The aim of this study was to examine the synergistic effect of doxorubicin (DOX) and histamine (His) in NPs DOX-loaded composed of poly(lactic) acid -PLA with histamine end groups (NPs-His-DOX) towards human gastric cancer cells (AGS) in vitro in conjunction with increasing oxidative stress, DNA damage, and cell apoptosis, as well as diminishing cell proliferation. The influence of studied NPs on the expression of intracellular adhesion molecule (ICAM)-1, which may facilitate the cytotoxic reaction of lymphocytes against gastric cancer cells, has also been determined. We showed a significant (p < 0.05) synergistic effect of His and DOX in the NPs His-DOX in increasing oxidative stress as demonstrated by an increased level of 4-hydroxynonenal (4HNE), DNA damage, cell apoptosis, in conjunction with a significant (p < 0.05) inhibition of cell proliferation as well as the disintegration of the cell monolayer. Furthermore, NPs His-DOX upregulated a cell deposition of ICAM-1. This study shows that NPs His-DOX facilitates the delivery of the anticancer drug DOX into the milieu of cancer cells, which results in increased cell death. Furthermore, upregulation of ICAM-1 on gastric cancer cells may increase anti-tumor cytotoxic activity of immunocompetent cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.